
51 - 200 employees
Founded 2004
đ§Ź Biotechnology
đ Pharmaceuticals
đ° $75M Post IPO equity on 2024-02
Biotechnology ⢠Pharmaceuticals
Liquidia is a biopharmaceutical company focused on developing inhaled therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company leverages its proprietary PRINTÂŽ particle engineering technology to create proprietary formulations and delivery methods aimed at improving efficacy, tolerability, and convenience of inhaled medicines; its pipeline includes inhaled treprostinil (commercial product) and clinical-stage candidates such as L606. Liquidia emphasizes patient support, clinical development, and advancing therapies for improved respiratory outcomes.
đĽ 7 minutes ago
đşđ¸ United States â Remote
â° Full Time
đ´ Lead
đ¨ââď¸ Medical Director
đť Ghost score 10%
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2004
đ§Ź Biotechnology
đ Pharmaceuticals
đ° $75M Post IPO equity on 2024-02
Biotechnology ⢠Pharmaceuticals
Liquidia is a biopharmaceutical company focused on developing inhaled therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company leverages its proprietary PRINTÂŽ particle engineering technology to create proprietary formulations and delivery methods aimed at improving efficacy, tolerability, and convenience of inhaled medicines; its pipeline includes inhaled treprostinil (commercial product) and clinical-stage candidates such as L606. Liquidia emphasizes patient support, clinical development, and advancing therapies for improved respiratory outcomes.
⢠Develop and lead integrated PK/clinical pharmacology strategies across assigned drug-development programs from early clinical development through late-stage development and regulatory submission ⢠Define key PK and exposure-response questions and establish strategies to address them ⢠Translate preclinical, translational, and early clinical PK findings into recommendations for dose selection, dose escalation, dosing regimen optimization, and study design ⢠Establish coherent PK strategies across individual clinical studies ⢠Provide strategic input into development plans, clinical protocols, statistical analysis plans, clinical study reports, investigator materials, regulatory documents, and responses to regulatory questions ⢠Evaluate effects of formulation, route of administration, device, dose, and patient population on systemic and local drug exposure ⢠Integrate PK data with pharmacodynamic, biomarker, efficacy, safety, and disease information for quantitative benefit-risk assessment and development decisions ⢠Identify modeling and simulation opportunities to accelerate development, reduce uncertainty, and optimize clinical trial design ⢠Provide PK leadership for SAD/MAD, food-effect, drug-drug interaction, special-population, bioavailability/bioequivalence, dose-ranging, and pivotal studies ⢠Develop fit-for-purpose PK sampling strategies and provide scientific input on sample collection, processing, bioanalytical requirements, and data management ⢠Partner with Clinical Operations and study teams to implement PK components in clinical protocols ⢠Review and interpret individual and population PK results and translate findings into clinical development recommendations ⢠Integrate PK assessments with safety, pharmacodynamic, biomarker, and efficacy endpoints ⢠Oversee external PK and pharmacometric vendors and CROs, including protocols, analysis plans, data review, deliverables, and quality ⢠Identify and resolve PK-related study issues and deviations ⢠Lead population PK analyses, including objectives, analysis strategies, covariate assessments, modeling approaches, simulations, and dose optimization ⢠Oversee and scientifically review NONMEM and other modeling and simulation analyses ⢠Communicate model assumptions, limitations, and conclusions ⢠Provide PK/clinical pharmacology leadership for inhaled drug-development programs, including pulmonary deposition, respiratory absorption, local versus systemic exposure, formulation, and device considerations ⢠Partner with formulation, device, CMC, translational, and clinical teams on formulation and device impacts on exposure and clinical performance ⢠Support interpretation of inhaled drug PK data in the context of local pulmonary pharmacology and systemic pharmacokinetics ⢠Provide senior-level PK and clinical pharmacology expertise in regulatory agency interactions ⢠Develop and review PK/clinical pharmacology sections of IND/IMPD, NDA/BLA/MAA, briefing documents, responses to information requests, and other regulatory materials ⢠Participate in regulatory meetings and provide rationale for PK strategies, modeling approaches, dose selection, and clinical pharmacology conclusions ⢠Anticipate regulatory questions and address PK and pharmacometric concerns ⢠Serve as senior PK subject-matter expert and strategic partner to Clinical Development and broader development teams ⢠Collaborate with Clinical Pharmacology, Biostatistics, Data Science, Translational Medicine, Biomarkers, CMC, Toxicology, Regulatory Affairs, and Clinical Operations ⢠Contribute quantitative clinical pharmacology expertise to program governance and portfolio decisions ⢠Communicate complex quantitative findings to technical and non-technical stakeholders ⢠Build relationships with internal stakeholders, external experts, academic collaborators, and strategic partners
⢠PhD or equivalent doctoral degree in Pharmacokinetics, Pharmacology, Pharmacometrics, Pharmaceutical Sciences, Clinical Pharmacology, Biopharmaceutics, or a closely related discipline ⢠Extensive experience in clinical pharmacokinetics and/or clinical pharmacology within the pharmaceutical or biotechnology industry ⢠Demonstrated experience developing and implementing PK strategies at the drug/asset level and individual clinical study level ⢠Strong experience with population PK and pharmacometric approaches, including interpretation and application of modeling and simulation to drug development decisions ⢠Demonstrated understanding of the drug-development process from early clinical development through late-stage development and regulatory submission ⢠Experience working cross-functionally in multidisciplinary drug-development teams ⢠Experience providing scientific leadership for internal teams and external CROs or consultants ⢠Strong understanding of PK study design, PK sampling strategies, bioanalysis, PK data interpretation, and clinical pharmacology principles ⢠Experience contributing to regulatory submissions and/or direct interactions with health authorities ⢠Excellent scientific communication skills, with the ability to translate complex PK and modeling results into clear development recommendations ⢠Demonstrated ability to operate strategically while maintaining sufficient technical depth to critically evaluate PK and pharmacometric work ⢠Preferred: Experience with inhaled drug development, pulmonary delivery, respiratory therapies, or other locally administered drugs ⢠Preferred: Experience with exposure-response modeling and/or pharmacodynamic modeling ⢠Preferred: Experience using or overseeing NONMEM, Monolix, or comparable population PK/pharmacometrics platforms ⢠Preferred: Experience with clinical trial simulation and model-informed drug development (MIDD) ⢠Preferred: Experience with physiologically based pharmacokinetic (PBPK) modeling and simulation ⢠Preferred: Experience supporting dose selection and optimization across different patient populations ⢠Preferred: Experience with special populations, including renal or hepatic impairment, pediatrics, elderly populations, or other clinically relevant populations ⢠Preferred: Experience with drug-drug interaction assessment and/or transporter-mediated interactions ⢠Preferred: Experience with regulatory interactions specifically related to clinical pharmacology, PK, population PK, and modeling and simulation ⢠Preferred: Peer-reviewed publications, conference presentations, or other evidence of scientific leadership in clinical pharmacology, pharmacokinetics, or pharmacometrics
⢠Competitive compensation package ⢠Medical insurance ⢠Dental insurance ⢠Vision insurance ⢠Short-term disability (STD) ⢠Long-term disability (LTD) ⢠401(k) Savings Retirement Plan ⢠Employee Stock Purchase Plan (ESPP) ⢠Reasonable accommodation for qualified individuals with disabilities
Apply NowđĽ 4 hours ago
Clinical Director leading clinical quality, supervision, and program development at a New York outpatient mental-health practice. Overseeing compliance, staff development, and care operations.
đĽ 4 hours ago
Physician leader advancing Labcorp Oncologyâs diagnostic medical affairs for hematologic malignancies and precision oncology. Leading scientific education, stakeholder engagement, market access, and evidence generation.
đşđ¸ United States â Remote
đľ $320k - $340k / year
đ° Post-IPO Debt on 2019-06
â° Full Time
đ´ Lead
đ¨ââď¸ Medical Director
đŚ H1B Visa Sponsor
đĽ 11 hours ago
Medical Director leading utilization management, quality improvement, and complex appeals for Centene. Coordinating clinical decisions, provider collaboration, and high-risk patient care.
đşđ¸ United States â Remote
đľ $236.5k - $449.3k / year
â° Full Time
đ´ Lead
đ¨ââď¸ Medical Director
đĽ 12 hours ago
Clinical Trial Liaison Director supporting Kardiganâs cardiovascular clinical trials across the U.S. West. Driving investigator engagement, site feasibility, recruitment, and study execution.
đşđ¸ United States â Remote
đľ $253k - $329k / year
â° Full Time
đ´ Lead
đ¨ââď¸ Medical Director
đĽ 12 hours ago
Utilization Management Medical Director leading clinical oversight, quality improvement, and utilization review. Advancing value-based care across Altaisâs California physician-led healthcare network.
đşđ¸ United States â Remote
đľ $186k - $223.2k / year
â° Full Time
đ´ Lead
đ¨ââď¸ Medical Director